Lyell Immunopharma, Inc.

Name: Lyell Immunopharma, Inc. standardized financial statements, quarterly
Creator: Listed

LYELNasdaqCIK 1806952HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$4.0k, Q2 FY2026

Operating income−$47.3m, Q2 FY2026

Net income−$44.8m, Q2 FY2026

Lyell Immunopharma, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Research and development	$m	43.8	47.0	43.2	40.3	39.5	not reported	43.4	34.9	28.2	not reported	36.6	39.5
Operating income	$m	(59.0)	(59.5)	(55.6)	(51.5)	(50.5)	(201)	(57.4)	(47.1)	(37.3)	(128)	(44.3)	(47.3)
Net income	$m	(50.9)	(52.9)	(60.7)	(45.8)	(44.6)	(192)	(52.2)	(42.7)	(38.8)	(141)	(24.2)	(44.8)
Diluted EPS	$ per share	(0.20)	not reported	(0.24)	(3.59)	(3.48)	not reported	(3.54)	(2.89)	(2.13)	not reported	(1.10)	(1.92)
Basic EPS	$ per share	(0.20)	not reported	(0.24)	(3.59)	(3.48)	not reported	(3.54)	(2.89)	(2.13)	not reported	(1.10)	(1.92)

Balance sheet

Cash and equivalents$73.0m, Q2 FY2026

Shareholders' equity$233.8m, Q2 FY2026

Lyell Immunopharma, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	286	146	126	133	100	106	120	98.8	124	60.2	90.8	73.0
Current assets	$m	587	555	534	500	450	380	309	282	328	261	267	214
Total assets	$m	795	750	694	654	619	491	430	385	408	340	351	311
Current liabilities	$m	35.1	34.5	32.4	30.9	33.5	53.8	41.3	36.9	31.9	49.4	36.9	39.9
Total liabilities	$m	97.4	95.1	91.1	87.6	88.5	108	93.3	86.5	78.8	91.9	77.0	77.3
Shareholders' equity	$m	698	655	603	567	531	383	337	299	329	248	274	234

Cash flow

Operating cash flow−$33.9m, Q2 FY2026

Capital expenditure$256.0k, Q2 FY2026

Lyell Immunopharma, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(37.7)	(40.6)	(42.0)	(38.1)	(35.0)	(47.2)	(54.7)	(34.5)	(28.6)	(32.3)	(38.5)	(33.9)
Capital expenditure	$m	0.2	0.0	0.0	0.3	0.1	0.0	0.2	0.2	0.1	0.3	0.1	0.3
Share repurchases	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)23.36m, Q2 FY2026

Lyell Immunopharma, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	248	250	250	251	254	12.8	12.8	14.8	14.8	18.3	21.9	23.4

Shares outstanding: 24.51m at Aug 3, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.